Karuna Therapeutics Reports Second Quarter 2020 Financial Results and Business HighlightsBusiness Wire • 08/05/20
Karuna Therapeutics Announces Topline Data From Phase 1b Trial Evaluating KarXT on Experimentally Induced Pain in Healthy VolunteersBusiness Wire • 08/03/20
Karuna Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with SchizophreniaBusiness Wire • 06/23/20
Surging Earnings Estimates Signal Good News for Karuna Therapeutics (KRTX)Zacks Investment Research • 05/20/20
Karuna Therapeutics, Inc. (KRTX) Shares March Higher, Can It Continue?Zacks Investment Research • 04/22/20
Karuna Therapeutics' Crash Reminds Investors How Dangerous Biotech Stocks Can BeThe Motley Fool • 12/23/19
Karuna's Drug Mechanism Of Action Established After Latest Positive Trial Readout In Schizophrenia StudySeeking Alpha • 11/27/19